Generic Name

Mexiletine

FDA approval date: June 05, 1995
Classification: Antiarrhythmic
Form: Capsule

What is Mexiletine?

Mexiletine hydrochloride capsules USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

An Open-Label, Randomized, Cross-Over Study to Investigate the Efficacy and Safety of Mexiletine PR Compared to Mexiletine IR in Patients With Non-Dystrophic Myotonias (ACHILLES Study)
An Open-Label, Randomized, Cross-Over Study to Investigate the Efficacy and Safety of Mexiletine PR Compared to Mexiletine IR in Patients With Non-Dystrophic Myotonias (ACHILLES Study)
Enrollment Status: Recruiting
Publish Date: September 25, 2025
Intervention Type: Drug
Study Phase: Phase 3

Summary: An Open-Label, Randomized, Cross-Over Study to Investigate the Efficacy and Safety of Mexiletine PR compared to Mexiletine IR in Patients with Non-Dystrophic Myotonias (ACHILLES study)

Prospective, Long Term, Observational Study (Patient Registry) of Paediatric Myotonic Disorders From Birth to Less Than Six Years of Age Who Are Treated With Mexiletine (PEGASUS Study).
Prospective, Long Term, Observational Study (Patient Registry) of Paediatric Myotonic Disorders From Birth to Less Than Six Years of Age Who Are Treated With Mexiletine (PEGASUS Study).
Enrollment Status: Recruiting
Publish Date: September 23, 2025
Intervention Type: Drug

Summary: This is a prospective, open-label, multi-centre, single arm, registry study to collect standard relevant clinical and epidemiological data during routine medical evaluation and treatment in paediatric patients with myotonic disorders who are being treated with mexiletine therapy according to the physician.

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Once Daily Mexiletine PR During 26 Weeks of Treatment in Patients With Myotonic Dystrophy Type 1 and Type 2 (Phase 3)
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Once Daily Mexiletine PR During 26 Weeks of Treatment in Patients With Myotonic Dystrophy Type 1 and Type 2 (Phase 3)
Enrollment Status: Recruiting
Publish Date: August 28, 2025
Intervention Type: Drug
Study Phase: Phase 3

Summary: A Randomized, Double-blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Once Daily Mexiletine PR During 26 Weeks of Treatment in Patients with Myotonic Dystrophy Type 1 and Type 2 (HERCULES study)

View All Clinical Trials

Related Latest Advances

Advanced Cardiotoxicity Profiling Using Field Potential Imaging with UHD-CMOS-MEA in Human iPSC-Derived Cardiomyocytes.
Advanced Cardiotoxicity Profiling Using Field Potential Imaging with UHD-CMOS-MEA in Human iPSC-Derived Cardiomyocytes.
Journal: Toxicological sciences : an official journal of the Society of Toxicology
Published: September 30, 2025
Mexiletine as Adjunctive Therapy in Atrial Fibrillation Following Dofetilide Treatment Failure.
Mexiletine as Adjunctive Therapy in Atrial Fibrillation Following Dofetilide Treatment Failure.
Journal: Circulation. Arrhythmia and electrophysiology
Published: September 25, 2025
Implantable Cardioverter Defibrillators for Long QT syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia? (Not so fast, Louis).
Implantable Cardioverter Defibrillators for Long QT syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia? (Not so fast, Louis).
Journal: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
Published: September 15, 2025
View All Latest Advances